The synthetic AHR-specific competitive antagonist CH223191, 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl]-1H-pyrazole-5-carboxamide (Tocris Bioscience, Bristol, United Kingdom), was solubilized in dimethyl sulfoxide (DMSO) and used at a concentration of 1.25, 2.5, 5, 10, 20, 40, and 80 µM.
The tryptophan metabolite L-kynurenine, (2S)-2-Amino-4-(2-aminophenyl)-4-oxo-butanoic acid (Sigma-Aldrich, St. Louis, MO, USA) was solubilized in DMSO and used at a concentration of 2.5, 5, 10, 20, 40, 80, 160, and 320 µM.
All treatments were performed in the absence of light, given that the compounds present photosensitivity.
The tryptophan metabolite L-kynurenine, (2S)-2-Amino-4-(2-aminophenyl)-4-oxo-butanoic acid (Sigma-Aldrich, St. Louis, MO, USA) was solubilized in DMSO and used at a concentration of 2.5, 5, 10, 20, 40, 80, 160, and 320 µM.
All treatments were performed in the absence of light, given that the compounds present photosensitivity.
Free full text: Click here
